CRGX | CARGO Therapeutics, Inc. Common Stock Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	23.92 - 25.16
52 Week Range	13.14 - 33.92
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	100,965
Average Volume	267,674
Shares Outstanding	45,904,633
Market Cap	1,132,467,296
Sector	Healthcare
Industry	Biotechnology
IPO Date	2023-11-13

Valuation
Profitability
Growth
Health
P/E Ratio	-1.40
Forward P/E Ratio	N/A
EPS	-17.64
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	150
Country	USA
Website	CRGX

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

*Chart delayed

Analyzing fundamentals for CRGX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is passable. For more detailed analysis please see CRGX Fundamentals page.

Watching at CRGX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on CRGX Technicals page.